Schott Pharma Stock - analyst update points to cautious view

Edited by ad hoc news Thu Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 20:24 UTC. Details in the imprint.

Schott Pharma (DE000A3ENQ51) is back on the radar after a dated analyst update from RBC Capital Markets. Finanzen.at reports the house kept Sector Perform on the stock.

What the update says

Finanzen.at shows RBC Capital Markets with a Sector Perform call on Schott Pharma and a current price reference of EUR 16.58. The page dates the update to 06/18/2026 and lists an implied distance to target of 4.77%.

That makes the note a clean sentiment marker rather than a fresh company announcement. The stock still trades with the analyst framing attached to it, not with a new operational event.

What the chart shows

The shares trade on Xetra, and Brain47 lists the stock at EUR 16.70 with a market value of EUR 2.25 billion. The same page shows a 30-day trend of +3.5% and a technical score of 57.

For a Thursday chart read, that places the stock in a narrow technical lane rather than in a dramatic breakout setup. The move profile remains more measured than broad-market headlines often suggest.

The business behind the stock

Schott Pharma supplies containment and drug-delivery solutions for injectable medicines. Its portfolio includes prefillable glass syringes, cartridges, and vials for pharmaceutical customers.

The company ties its growth story to drug stability, sterile packaging, and the shift toward complex biologics. That business mix is what analysts keep pricing when they reassess the stock.

Where the stock trades today

The shares of Schott Pharma (DE000A3ENQ51) trade on Xetra at EUR 16.70 as of 06/18/2026, 20:24 UTC.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.